Health insurance marketer faces fines, sanctions for lying about plans it sells


Benefytt Technologies, Inc. would have to refund $100 million and stop misleading customers about coverage.

Benefytt Technologies, Inc., a marketer of health care plans, could have to refund $100 million to customers and face additional penalties under a complaint filed against the company by the Federal Trade Commission (FTC).

According to an FTC news release, the complaint alleges that Benefytt, two subsidiaries, and two of its top executives lied about the coverage the company’s plans provided. It also says that Benefytt used deceptive lead generation websites to lure customers and charged for add-on products without customers’ permission. The complaint names former Benefytt CEO Gavin Southwell and former vice president of sales Amy Brady.

Benefytt, based in Tampa, Florida, sells association memberships and other health care-related products, often through telemarketing companies and lead generators. Southwell was president and CEO of the company from 2016 to 2021, while Brady was vice president of sales for more than a decade before also leaving in 2021.

“Benefytt pocketed millions selling sham insurance to seniors and other consumers looking for health coverage,” Samuel Levine, JD, director of the FTC’s Bureau of Consumer Protection, said in the release. “The company is being ordered to pay $100 million, and we’re holding its executives accountable for this fraud.”

The complaint alleges that Benefytt and its partners used high-pressure sales tactics to deceive consumers into believing they were buying comprehensive health insurance plans and charging hundreds of dollars per month for products and services that left them unprotected in a medical catastrophe. It charges that Benefytt’s sales process harmed consumers by:

  • Lying about the nature of the plans: Agents claimed the plans were qualified under the Affordable Care Act, meaning they included benefits such as preventive care and caps on out-of-pocket medical costs, when the plans were not even comprehensive health insurance
  • Bundling and charging fees for unwanted products: Plans often included products such as life or accident insurance and fitness programs, and did not clearly disclose the separate costs of these products so consumers were unaware they were buying them
  • Making cancellation difficult: The complaint charges that consumers who called to cancel their plans were often transferred to the sales agents who deceived them in the first place.

The release says that Benefytt and two of its subsidiaries have agreed to a proposed court order that would require them to:

  1. Pay $100 million to the FTC, which the FTC will refund to consumers harmed by the defendants’ practices
  2. Notify current Benefytt customers of the FTC’s complaint against the company and allow them to cancel their enrollment. The company must also refund payments made after the court order is approved to customers who cancel immediately
  3. Stop misleading consumers about their products’ features, including whether they are ACA-compliant, disclose facts such as total costs and limitations prior to purchase, and get customers’ informed consent before billing them for anything
  4. Closely monitor all companies selling their products to ensure they aren’t using deceptive or misleading sales tactics

Separate proposed court orders would prohibit Southwell and Brady from playing any role in selling or marketing any health care-related product or service.

The complaint and proposed final orders were filed in the U.S. District Court for the Middle District of Florida. They become enforceable after they are signed by a judge.

This article originally appeared on Medical Economics®.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.